Back to top

Analyst Blog

We have retained our Neutral recommendation on Health Net Inc. (HNT - Analyst Report) as the declining membership and deteriorating Government Contracts segment results are expected to weigh on the positives of the company. This managed healthcare company carries a Zacks Rank #3 (Hold).

Why Reiterate?

We remain concerned with the rate of customer attrition in Health Net’s health plans in the recent years. Revenues from the Government Contract segment have also been declining due to changes in the TRICARE and Military and Family Life Consultant contracts.

Nevertheless, Health Net had a strong capital and liquidity position with total cash and investments of approximately $2.0 billion at the end of Sep 2012. Additionally, the investment portfolio of the company is strong, with an average rating of “A+” and “A1” as per Standard & Poor’s and Moody’s Investor Service of Moody’s Corp. (MCO - Analyst Report), respectively.

Moreover, Health Net’s total expenses have been declining since 2010. Lower expenses can significantly improve the company’s margins as well as bottom-line results. Further, the company has been slowly disposing of its non-profitable businesses to improve its bottom line.

Health Net’s third-quarter 2012 operating income, which includes combined net earnings from the Western Region and Government Contracts segments, came in at 38 cents per share, declining substantially from the year-ago level of 84 cents per share. The company expects operating earnings per share between $1.00 and $1.10 in 2012. The Zacks Consensus Estimate of $1.04 per share lies within this guidance range.

The company is scheduled to release its fourth quarter and full year 2012 financial results before the opening bell on Jan 30, 2013. The Zacks Consensus Estimate for fourth quarter stands at 37 cents per share, down 61% year-over-year.

Other Stock to Consider

Although we have a cautious stance on Health Net, other stocks like American Caresource Holdings, Inc. and Molina Healthcare, Inc. (MOH - Analyst Report), both carrying a Zacks Rank #2 (Buy), are worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%